Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

Performance of RNAC Cartesian Therapeutics | -20.6% in 12m

Compare RNAC with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?

Compare Cartesian Therapeutics with its related Sector/Index XBI

Compare Cartesian Therapeutics with its related Sector/Index XBI

Performance Duell RNAC vs XBI

TimeFrame RNAC XBI
1 Day 0.34% -1.52%
1 Week 24.9% 3.45%
1 Month 42.9% 7.71%
3 Months 11.9% -2.11%
6 Months -17.7% 25.51%
12 Months -20.6% 6.37%
YTD 34.5% 1.05%
Rel. Perf. 1m 2.94
Rel. Perf. 3m 2.69
Rel. Perf. 6m -3.96
Rel. Perf. 12m -3.06

Is Cartesian Therapeutics a good stock to buy?

No, based on ValueRay Fundamental Analyses, Cartesian Therapeutics (NASDAQ:RNAC) is currently (May 2024) a stock to sell. It has a ValueRay Fundamental Rating of -72.10 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RNAC as of May 2024 is 21.63. This means that RNAC is currently overvalued and has a potential downside of -18.16% (Sold with Premium).

Is RNAC a buy, sell or hold?

  • Strong Buy: 0
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
Cartesian Therapeutics has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy RNAC.
Values above 0%: RNAC is performing better - Values below 0%: RNAC is underperforming

Compare RNAC with Broad Market Indices

Symbol 1w 1m 6m 12m
US S&P 500 SPY 23.20% 37.09% -35.95% -49.98%
US NASDAQ 100 QQQ 22.66% 36.77% -35.13% -57.98%
US Dow Jones Industrial 30 DIA 23.49% 36.69% -33.13% -42.65%
German DAX 40 DBXD 25.25% 37.89% -34.65% -37.40%
UK FTSE 100 ISFU 23.35% 33.06% -34.52% -36.00%
Shanghai Shenzhen CSI 300 CSI 300 23.74% 38.34% -20.99% -12.96%
Hongkong Hang Seng HSI 21.12% 19.58% -22.70% -15.27%
Japan Nikkei 225 EXX7 24.48% 43.36% -29.15% -32.44%
India NIFTY 50 INDA 21.74% 38.94% -35.24% -49.35%
Brasil Bovespa EWZ 24.41% 37.62% -15.83% -32.96%

RNAC Cartesian Therapeutics vs. Sectors

Symbol 1w 1m 6m 12m
Communication Services XLC 23.85% 39.55% -36.17% -58.11%
Consumer Discretionary XLY 24.51% 39.16% -25.00% -40.30%
Consumer Staples XLP 24.09% 36.28% -31.90% -26.21%
Energy XLE 23.65% 41.98% -31.78% -45.85%
Financial XLF 23.27% 35.81% -40.08% -53.70%
Health Care XLV 22.96% 37.18% -32.67% -34.13%
Industrial XLI 25.13% 39.38% -37.35% -48.96%
Materials XLB 24.51% 39.32% -33.68% -41.25%
Real Estate XLRE 22.34% 34.38% -27.30% -30.61%
Technology XLK 21.79% 36.34% -33.98% -58.94%
Utilities XLU 23.35% 29.97% -35.86% -33.31%
Aerospace & Defense XAR 24.08% 34.40% -33.20% -44.78%
Biotech XBI 21.40% 35.15% -43.17% -27.00%
Homebuilder XHB 25.17% 36.52% -48.17% -71.48%
Retail XRT 22.77% 35.40% -38.50% -45.82%

RNAC Cartesian Therapeutics vs. Commodities

Symbol 1w 1m 6m 12m
Oil USO 22.63% 45.32% -26.45% -39.78%
Natural Gas UNG 9.23% 10.04% 4.82% 10.17%
Gold GLD 22.59% 41.01% -39.43% -42.03%
Silver SLV 13.13% 31.49% -50.03% -52.57%
Copper CPER 16.59% 28.15% -51.58% -55.89%

Returns of RNAC vs. Yields & Bonds

Symbol 1w 1m 6m 12m
iShares 20+ Years Bond TLT 23.44% 40.14% -21.17% -13.11%
iShares High Yield Corp. Bond HYG 24.36% 40.34% -24.22% -31.48%
Does Cartesian Therapeutics outperform its market, is RNAC a Sector Leader?
No, over the last 12 months Cartesian Therapeutics (RNAC) made -20.63%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.37%.
Over the last 3 months RNAC made 11.93%, while XBI made -2.11%.
Period RNAC XBI S&P 500
1 Month 42.86% 7.71% 5.77%
3 Months 11.93% -2.11% 6.32%
12 Months -20.63% 6.37% 29.35%